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Hepatocellular carcinoma (HCC) has an elevated mortality rate, largely because
of high recurrence and metastasis. Additionally, the main obstacle during
treatment of HCC is that patients usually develop resistance to chemotherapy.
Cancer drug resistance involves many different mechanisms, including
alterations in drug metabolism and processing, impairment of the apoptotic
machine, activation of cell survival signaling, decreased drug sensitivity and
autophagy, among others. Nowadays, miRNAs are emerging as master
regulators of normal physiology- and tumor-related gene expression. In HCC,
aberrant expression of many miRNAs leads to chemoresistance. Herein, we
particularly analyzed miRNA impact on HCC resistance to drug therapy. Certain
miRNAs target ABC (ATP-binding cassette) transporter genes. As most of these
miRNAs are downregulated in HCC, transporter levels increase and intracellular
drug accumulation decrease, turning cells less sensitive to death. Others miRNAs
target autophagy-related gene expression, inhibiting autophagy and acting as
tumor suppressors. Nevertheless, due to its downregulation in HCC, these
miRNAs do not inhibit autophagy or tumor growth and, resistance is favored.
Concluding, modulation of ABC transporter and/or autophagy-related gene
expression or function by miRNAs could be determinant for HCC cell survival
under chemotherapeutic drug treatment. Undoubtedly, more insights on the
biological processes, signaling pathways and/or molecular mechanisms
regulated by miRNAs are needed. Anyway, miRNA-based therapy together with
conventional chemotherapeutic drugs has a great future in cancer therapy.
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miRNA
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Core tip: The main obstacle during treatment of hepatocellular carcinoma (HCC) is
resistance to chemotherapy. We analyzed microRNAs (miRNAs) impact on HCC
chemoresistance. Certain miRNAs target ABC transporter genes. As most of these
miRNAs are downregulated in HCC, transporter levels increase and intracellular drug
accumulation decrease, turning cells less sensitive to death. Others miRNAs target
autophagy-related gene expression, inhibiting autophagy and acting as tumor
suppressors. Nevertheless, due to its downregulation in HCC, these miRNAs do not
inhibit autophagy or tumor growth and, resistance is favored. ABC transporter and/or
autophagy-related gene expression modulated by miRNAs affect HCC cell survival
under chemotherapy.
Citation: Espelt MV, Bacigalupo ML, Carabias P, Troncoso MF. MicroRNAs contribute to
ATP-binding cassette transporter- and autophagy-mediated chemoresistance in hepatocellular




Hepatocellular carcinoma (HCC) accounts for around 80%-90% of liver cancer. It’s the
fifth most common cancer worldwide and the third cancer-related death cause. In
general, HCC develops in a background of cirrhosis. The main factors that contribute
to  this  tumor are  infections  with  hepatitis  B  or  C virus,  alcohol  abuse  and non-
alcoholic fatty liver disease[1]. Despite the development of early detection methods,
80% of HCC patients are diagnosed at a stage of the disease so advanced that the
patient’s survival is just of about few months[2].  When HCC is diagnosed at early
stages the most effective approaches are partial hepatectomy or liver transplantation,
however in most patients the tumor is not detected promptly or it is hard to find a
compatible donor.  In intermediate stages,  transarterial  chemoembolization is the
treatment  of  choice [3 ].  For  patients  with  unresectable  HCC,  sorafenib  oral
administration slightly improves survival[4]. Even the ones who qualify for surgery
have a modest improvement in the survival because of its high rate of recurrence,
occurring in more than 90% of patients[2].
Treatment with anti-cancer drugs (chemotherapy) can destroy tumor cells helping
patients to control cancer growth. Some of these drugs to treat HCC are 5-fluorouracil
(5-FU),  cisplatin,  doxorubicin[5],  paclitaxel  and  the  multitarget  tyrosine  kinase
inhibitor sorafenib. But unfortunately, liver cancer patients usually develop drug
resistance to chemotherapy[6]. Cancer drug resistance is a multifactorial phenomenon
involving many different mechanisms such as gene mutation, DNA repair pathway
aberrations, impairment of the apoptotic machine, alterations in drug metabolism and
processing,  activation  of  cell  survival  signaling  and  escape  of  drug  sensitivity,
autophagy,  epigenetic  regulation,  altered  lipid  metabolism  and  tumor
microenvironment participation[2]. Among these mechanisms, modifications in drug
uptake or efflux produce a diminished intracellular drug concentration, leading to
tumor cell survival and resistance to death. Until some years ago, the reduction of
intracellular drug concentration was thought to be the only important mechanism for
resistance. Nevertheless, many other processes have been appeared to be involved
more lately. Autophagy is one of these novel processes that also contribute to tumor
chemotherapy  resistance;  moreover,  autophagy  inhibitors  are  used  to  sensitize
different cancers to chemotherapy. Under this scenario, microRNAs (miRNAs) are
nowadays emerging as master regulators of normal physiology- and tumor-related
gene expression. Thus, it  is  not surprising that these molecules can also regulate
chemoresistance.
In  this  review we summarize  the findings from the last  decade regarding the
molecular mechanisms of chemoresistance in HCC, focusing on the involvement of
miRNAs. We especially highlight the role of these molecules in drug efflux through
ABC (ATP-binding cassette) transporters and autophagy.
miRNAs IN THE DEVELOPMENT OF HCC
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CHEMORESISTANCE
miRNAs are short RNA molecules of 18-25 nucleotides in length. They are non-coding
molecules  that  regulate  the  expression  of  many  genes.  By  binding  to  the  3’-
untranslated region (UTR) of target genes through base complementarity, miRNAs
lead to mRNA degradation or translational repression, acting as negative regulators
of gene expression[6]. Many reports have described a role of these molecules in the
control  of  diverse biological  processes such as development,  differentiation,  cell
proliferation and apoptosis[7]. They can also act as oncogenes or tumor suppressors in
different human cancers.
Up to date more than 2500 miRNAs have been described in humans and each of
them has been reported to silence more than one gene. miRNAs take a crucial part in
different processes in normal and abnormal liver development. They are involved in
lipid,  cholesterol  and  glucose  metabolism,  and  liver  differentiation  (see  Ref.[8]
review). They take part in apoptosis, necrosis, cell cycle, proliferation, epithelial-
mesenchymal  transition  and  inflammation[9].  Further,  studies  derived  from  the
comparison between normal  liver  and human liver  cancer  showed the  aberrant
expression of many miRNAs in cancer cells. It was interesting to find that some of
them such as, miR-21, miR-221 and miR-222 are upregulated in HCC whereas miR-
122, miR-199 and the let7 family members are downregulated[7], showing the complex
pattern  of  miRNA  expression  in  this  type  of  cancer.  Regarding  the  molecular
mechanisms,  protein  kinase  B  (AKT),  mammalian  target  of  rapamycin  (mTOR),
Wingless-type MMTV integration site family (Wnt), Janus kinase/signal transducers
and activators of transcription (JAK/STAT), and Mitogen-activated protein kinases
(MAPK) are the main miRNA-regulated pathways during HCC tumorigenesis[10].
Thus, many miRNAs are deregulated in HCC and some of them participate in the
progression  of  chemoresistance [11].  Nevertheless,  their  precise  roles  in  the
development  of  drug resistance  in  liver  cancer  are  not  fully  understood.  In  the
following sections we particularly analyze the relationship between miRNAs and
ABC transporter-mediated drug resistance in HCC. Besides, we summarize the novel
evidence that relates miRNAs, autophagy and chemoresistance in HCC.
miRNAs AND ABC TRANSPORTER-MEDIATED DRUG
RESISTANCE IN HCC
The ABC transporters are cell membrane proteins that couple the hydrolysis of ATP
to  extrude  different  types  of  xenobiotics  and  metabolites  against  concentration
gradient. Efflux transporters such as P-glycoprotein (P-gp/ABCB1),  breast cancer
resistance protein (BCRP/ABCG2)  and multidrug resistance-associated protein 1
(MRP1/ABCC1),  among others, limit the exposure to chemotherapeutic drugs by
extruding them from cells. Consequently, these transporters are main actors in the
drug  resistance  phenomenon.  Furthermore,  their  overexpression  in  HCC  cells
represents a big obstacle for chemotherapy treatment and the central mechanism that
contributes to drug resistance[12]. Here we summarize the recent studies describing the
role of major miRNAs on ABC transporter family proteins and their impact on HCC
chemoresistance.
miR122
This  is  a  liver  specific  miRNA[13]  and  it  participates  in  lipid  and  cholesterol
metabolism  and  its  decreased  expression  has  detrimental  effects  on  the  liver[8].
Frequently, miR122 is downregulated in HCC tumors denoting poor prognosis and
metastatic properties[14]. In human HCC cell lines (HepG2, HuH-7, Hep3B), miR122
levels were also found reduced. Interestingly, when these cells were adenovirus-
transduced  to  overexpress  miR122  they  became  more  sensitive  to  DOX-  and
vincristine-induced death. Remarkably, miR122-overexpressing HCC cells showed
reduced levels of ABCB1 and ABCC1 mRNA expression (Table 1). The latter was also
found downregulated at  the  protein  level[12].  These  results  indicate  that  miR122
controls sensitivity to drug-induced HCC cell death by downregulating P-gp and
MRP1 expression.
miR27a
miR27a is involved in tumorigenesis in different types of cancers. In leukemia cells it
was shown that resistance to DOX correlates with high expression of P-gp and low
levels of miR27a. The upregulation of this miRNA produced greater mortality in the
presence of DOX than the observed in control cells, demonstrating the role of miR27a
in chemoresistance in leukemia cells[15]. On the contrary, miR27a upregulation lead to
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Table 1  miRNAs and ABC transporter-mediated drug resistance in hepatocellular carcinoma cells
miRNA Expression Level in HCC







miR122 Downregulated in tumors
(reduced levels correlate with
patient poor prognosis and
metastasis) and in human
HepG2, HuH-7 and Hep3B
HCC cell lines
miR122-overexpressing HCC
cells treated with DOX and
vincristine showed reduced
levels of P-gp mRNA
expression, and MRP1
mRNA and protein levels
Adenovirus-transduced cells
to overexpress miR122




miR27a Low in drug-resistant Bel-
7402 cells
Negatively correlated with P-
gp levels. Upregulation of




sensitized resistant cells to 5-
FU, mitomycin and DOX
[17]
miR503 Downregulated in HCC
tissues (reduced levels
correlate with malignant
tumor progression), in HCC
cell lines (SMMC-7721,
Hep3B, HepG2, MHCC97H




downregulation of both P-gp






restored sensitivity to DOX in
HepG2 resistant cells
[19,20]
miR375 Downregulated in patient








tumor cell growth in vitro and
in vivo
[21,22,24]
miR133a Downregulated in patient
tumor tissues (its low
expression correlated with
poor differentiated tumors)
and in HepG2, SMMC-77231,
Hep3B, HuH-7 HCC cells
Through its binding to the








miR326 Downregulated in human
tissues (its low expression
correlated with tumor
progression and lymph node





binding to the 3’UTR of
ABCC1 gene
miR326-overexpressing
HepG2 cells were more
sensitive to DOX than control
cells
[28,31]
miR223 Downregulated in HCC
patient sera and liver biopsies
Through its binding to the




increased sensitivity to DOX
and paclitaxel in SMMC-7721
and HepG2 cells
[34,35]
miR491-3p Downregulated in HCC
tissues and in human cell
lines (Hep3B, Bel-7402 and
SMMC-7721 cells)
Negatively correlated with P-
gp expression. Through its
binding to the 3’UTR of







factor suggested to induce P-
gp expression).
Conferred sensitivity to DOX
and vinblastine in Hep3B and
SMMC-7721 HCC cells
[38]
miR183 Overexpressed in liver tissues
and in drug-resistant Bel-7402
cells
Positively correlated with P-
gp and MRP2 protein
expression
Conferred resistance to 5-FU
in Bel-7402 cells
[41,42]
miRNA: MicroRNA; ABC: ATP-binding cassette; HCC: Hepatocellular carcinoma; DOX: Doxorubicin; 5-FU: 5-Fluoroacil; P-gp/ABCB1: P-glycoprotein;
MRP1/ABCC1: Multidrug resistance-associated protein 1; 3’-UTR: 3’-untranslated region; MRP2: Multidrug resistance-associated protein 2.
the overexpression of P-gp in ovarian cancer and cervical carcinoma cells[16].
There was no information about the relationship between the miR27a and ABC
transporters in HCC until 2013. Chen et al[17] developed Bel-7402 HCC cells resistant to
5-Fluoroacil (5-Fu). They found that these cells overexpressed P-gp while miR27a was
almost  undetectable.  But  when cells  were  transfected  with  miR27a,  the  authors
observed more sensitivity to 5-Fu, DOX and mitomycin, and diminished expression of
P-gp[17]  (Table  1).  Thus,  levels  of  miRNA27a  in  HCC  cells  are  low  and  seem  to
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negatively correlate with P-gp expression.
miR503
This  molecule  is  downregulated  in  some  types  of  cancers  such  as  gastric  and
endometrial  tumors,  while  it  is  overexpressed  in  others,  like  retinoblastoma or
parathyroid  carcinoma[18].  In  HCC samples,  this  miRNA is  downregulated  with
respect  to  non-tumor  liver  tissues,  and  this  low  level  is  related  to  malignant
progression[19]. Furthermore, the expression of miR503 in different HCC cell lines is
also decreased. Wang et al[20] found that miR503 was reduced in DOX-resistant HepG2
HCC cells. Besides, these cells overexpressed both P-gp and MRP1 transporters[20].
Further, HepG2 cells transfected to overexpress miR503 showed a reduction in the
expression of both transporters at protein level, and at mRNA level as well (Table 1).
Interestingly, cells overexpressing miR503 also showed an increased sensitivity to
DOX and accumulated more  intracellular  rhodamine-123[20].  This  fluorophore  is
known to be extruded from the cells through P-gp, therefore these results indicate
that miR503 controls sensitivity to DOX-induced death in HepG2 cells by reducing P-
gp and MRP1 expression and increasing intracellular drug concentration.
miR375
Initially, this molecule was identified in pancreatic cells. It regulates insulin secretion
so it takes part of glucose homeostasis. In many cancers, it is downregulated and acts
as a tumor suppressor[21]. In HCC, miR375 is one of the most downregulated miRNAs
in  tumor  tissues  and cell  lines.  Its  ectopic  overexpression  was  demonstrated  to
decrease  liver  cancer  cell  growth  and  invasion,  and  to  promote  apoptosis[21,22].
Moreover,  miR-375 suppressed astrocyte elevated gene-1 (AEG-1)  expression by
binding directly to its 3′-UTR[22], and AEG-1 overexpression increased P-gp protein
levels in HCC cells[23].
In  a  recent  study,  DOX-resistant  HepG2  cells  were  established  and  they
overexpressed P-gp. However, when miR375-containing lipid-coated nanoparticles
were delivered to these cells, P-gp expression decreased under control cell levels.
Also, in cell viability assays, the half inhibitory concentration (IC50) of different HCC
cell  lines  (HepG2,  HuH-7,  Hep3B and HepG2 resistant  to  DOX)  incubated with
nanoparticles  containing both DOX and miR375 was lower than the IC50  of  cells
cultured with DOX or nanoparticles containing DOX alone (Table 1). Importantly,
nanoparticles loaded with miR375 suppressed liver tumor growth, enhanced the
therapeutic effect of DOX and reduced drug toxicity in mice[24].
miR133a
This miRNA is downregulated in breast cancer cell lines and tissues, and this decrease
is  related  to  advanced  clinical  stages[25].  Besides,  it's  downregulation  has  been
associated with metastasis and recurrence of prostate cancer[26]. In HCC cell lines and
tissues, miR133a was also found downregulated and its low expression was related
with  poor  differentiated  tumors[27].  Interestingly,  predictions  performed  with
computational programs revealed that the 3’UTR of MRP1/ABCC1 transporter gene
includes a binding site for miR133a (and also for miR326). By luciferase reporter assay
it was confirmed that miR133a binds to the 3’UTR of ABCC1 gene and controls MRP1
expression. Remarkably, miR133a overexpression in HepG2 cells induced a significant
decrease in MRP1 mRNA and protein levels (Table 1). Besides, in the presence of
DOX, cells overexpressing miR133a were more sensitive to drug-induced death than
control cells[28].
miR326
This miRNA was found to be downregulated in gastric cancer[29]. In breast cancer cells
and  tissues  its  expression  negatively  correlated  with  MRP1  transporter  levels.
Furthermore, elevated miR326 levels sensitized cells to cytotoxic drugs[30]. In human
HCC tissues, this miRNA was also found downregulated and its reduced expression
correlated  with  tumor  malignancy  and patient  lymph node  metastasis.  In  vitro,
miR326 inhibited tumor cell proliferation and invasion, and promoted apoptosis in
vivo[31]. Regarding its role as modulator of ABC transporter expression, computational
programs predicted a binding site for miR326 at  the 3’UTR of ABCC1  gene.  This
binding site was also confirmed by luciferase reporter assay (Table 1). In addition, it
was demonstrated that  HCC cells  overexpressing miR326 had reduced levels  of
MRP1, both at mRNA and protein levels. Further, miR326-overexpressing HepG2
cells showed more sensitivity to DOX than control cells[28].
miR223
In colon cancer, miR223 is upregulated and acts as an oncogene. On the contrary, it is
frequently downregulated in leukemia and lymphomas[32]. In HCC, this miRNA is
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also  reduced  and  it  was  shown  to  induce  HepG2  and  Bel-7402  cell  growth
suppression and to promote apoptosis[33]. Moreover, lower miR223 levels were found
in HCC patient sera respect to healthy volunteers, and a reduced expression was also
determined in liver biopsies compared with normal liver. Thus, this miRNA has been
proposed as a novel potential biomarker for HCC[34].
Yang et al[35] showed that P-gp protein expression was higher in some HCC cell
lines such as Hep3B, HCC3, LM-6, SMMC7721, HuH-7 and HepG2, than in others like
Hep3B and BEL-7402 cells. Moreover P-gp levels positively correlated with DOX IC50.
Interestingly, using bioinformatics techniques miR223 was first predicted to bind to
the 3’UTR of ABCB1 gene. This was later confirmed by performing an EGFP reporter
assay where miR223 was proved to specifically interact with the 3’UTR of ABCB1
gene.  Further,  miR223  expression  was  found to  be  differentially  expressed  and
inversely correlated with P-gp levels when comparison was made among the eight
cell  lines.  Besides,  inhibition  of  miR223  expression  was  verified  to  induce  P-gp
expression in most of the HCC cell lines analyzed[35]. In addition, transfection of HCC
cells with miR223 mimics showed the inhibition of P-gp expression (Table 1), both at
mRNA and protein levels (Table 1), and an increase in cell mortality under paclitaxel
and DOX treatment. These results were confirmed by upregulating P-gp expression
and  through  a  rescue  experiment  by  overexpressing  ABCB1  lacking  the  3’UTR.
Therefore,  this  study demonstrates  that  miR223  has  a  relevant  role  in  HCC cell
chemoresistance by controlling P-gp expression[35].
miR491-3p
In multidrug-resistant cancer tongue cells, this miRNA was found to be decreased
and the  induction  of  its  expression  sensitized  cells  to  chemotherapy[36].  Also  in
osteosarcoma cells and tissues, miR491-3p was observed downregulated and when its
expression  was  restored,  the  suppression  of  tumor  growth  and  invasion  was
demonstrated[37].
Recently, it was demonstrated that this miRNA is also downregulated in HCC cell
lines. Furthermore, in liver tumors miR491-3p levels were reduced compared with
matched non-tumor tissues. Besides, P-gp levels were higher in HCC Hep3B, BEL-
7402 and SMMC-7721 cells than in normal human liver cell lines (THLE-2 and THLE-
3). Notably, P-gp expression inversely correlated with miR491-3p in both tumor and
normal  liver  cells  (Table  1).  This  negative  correlation was also  found in  clinical
samples[38]. Moreover, using bioinformatic algorithms, different miRNAs -including
miR491-3p-  were  predicted  as  candidates  to  bind  to  the  3’UTR  of  ABCB1  gene.
miR491-3p specific interaction with the 3’UTRs of ABCB1 was confirmed performing
luciferase reporter gene assays. Interestingly, specificity protein 3 (SP3, a transcription
factor suggested to induce ABCB1 expression) was demonstrated to be another target
of miR491-3p. miR491-3p levels inversely correlated with SP3 expression in both HCC
cells and liver tumors. Remarkably, Hep3B cells transfected with miR491-3p mimics
were more sensitive to DOX and vinblastine. On the contrary, overexpression of P-gp
or SP3 restored chemoresistance reverting the sensitivity conferred by miR491-3p.
Therefore, a loop including miR491-3p, SP3 and MDR1 in HCC cell chemoresistance
was proposed[38].
miR183
The expression of this miRNA is deregulated in some malignancies such as leukemia,
breast cancer and liver tumors[39]. miR183 downregulation correlated with metastasis
in lung cancer[40]; however, this mRNA was upregulated in HCC tissues as compared
to  the  adjacent  non-tumor  liver  zone[41].  Further,  the  programmed  cell  death  4
(PDCD4) tumor suppressor gene was downregulated in HCC cells transfected with
miR183[41]. Wang et al[42] showed that miR183 was overexpressed in HCC Bel-7402/5-
Fu (resistant to 5-FU) cells. P-gp and MRP2 protein expression was also increased in
Bel-7402/5-Fu cells (Table 1), and the suppression of miR183 in these cells diminished
P-gp and MRP2 protein levels. In addition, the authors established that high levels of
miR183 induced the expression of both transporters in control cells. So, these results
indicate that miR183 modulates P-gp and MRP2 expression.
Thus, a large amount of evidence points that many miRNAs are deregulated in
HCC and some of them are involved in chemoresistance.  Nevertheless,  until  the
recent years the precise mechanisms underlying miRNA-induced drug resistance in
this malignancy have not been fully understood. Many efforts have been targeted to
decipher  how  aberrantly  expressed  miRNAs  affect  tumor  cell  proliferation  or
apoptosis pathways. Here, we investigated thoroughly the recent findings that reveal
that certain miRNAs regulate ABC transporter expression by specifically targeting, for
instance,  ABCB1  and/or  ABCC1  genes.  Most  of  these  miRNAs  are  found
downregulated in HCC tissues and cells.  As a  consequence,  P-gp and/or MRP1
expression levels increase and intracellular therapeutic drug accumulation decrease,
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making HCC cells less sensitive to death (Table 1). Altogether, these findings indicate
that miRNAs have a key role in ABC transporter-mediated drug resistance in HCC.
AUTOPHAGY IN THE DEVELOPMENT OF HCC
CHEMORESISTANCE
Autophagy  is  an  evolutionary  conserved  mechanism  that  involves  proteolytic
degradation of cytosolic components at the lysosome through lysosomal enzyme
action that facilitate degradation of sequestered products[43].  It occurs mainly as a
response to cellular stress (infection, hypoxia, etc.) and its leading function is to grant
nutrients for cellular functions and to remove unwanted material from the cytosol
such as damaged organelles, acting as a cytoprotective system[44].
Autophagy  includes  five  phases:  initiation,  elongation  and  autophagosome
formation,  fusion,  and  autolysosome  formation.  This  process  begins  with  the
development  of  an  isolated  membrane,  called  phagophore,  which  origin  is
controversial. It expands and engulfs intracellular organelles or protein aggregates
(for example) in a double-membrane vesicle called autophagosome. Then, maturation
occurs  when  autophagosome  fuses  with  a  lysosome  to  form  an  autolysosome,
promoting the degradation of the inside contents. Finally, aminoacids, fatty acids, and
nucleotides are transported to the cytoplasm, so they can be re-used by the cell[43].
Thus,  autophagy  works  as  a  recycling  machinery  that  removes  non-functional
proteins and organelles.
The molecular pathway of autophagy has been thoroughly reviewed elsewhere[45,46].
Briefly, the initial phase is driven by the unc-51-like autophagy activating kinase
(ULK) complex and the class III phosphatidylinositol 3-kinase (PtdIns3K) complex.
The last complex produces phosphatidylinositol 3-phosphate for recruitment of other
factors  to  the  phagophore,  and contains  the  key  autophagy regulators  vacuolar
protein sorting 34 (VPS34),  VPS15,  Beclin 1  and activating molecule  in  Beclin 1-
regulated autophagy (AMBRA1). Downstream, the autophagy-related gene 8 (ATG8)
and  ATG12  systems  (two  ubiquitin-like  conjugation  systems)  mediate  vesicle
expansion. The E1-like protein ATG7 is required for activation of ATG8 [light chain 3
(LC3) in mammals] and ATG12. ATG8/LC3 is subjected to proteolysis and then is
covalently attached to the lipid phosphatidylethanolamine (in mammalian cells, the
precursor form is LC3-I and LC3-II is the lipidated one), by which it associates with
the phagophore  membrane.  Thus,  autophagy can be  detected biochemically  (by
assessing LC3-II generation) or microscopically (by observing LC3 puncta formation,
indicative of LC3 redistribution to the autophagosomes under development). The
pathway  includes  other  proteins  such  as  ATG9,  factors  required  for
autophagosome–lysosome fusion (e.g., lysosomal-associated membrane protein 2),
vacuolar permeases that mediate amino acid efflux from the lysosome, and lysosomal
enzymes involved in cargo degradation[45,46].
In normal liver, damaged mitochondria and mutated cells are removed through
autophagy, and this mechanism suppresses tumor initiation. But once the tumor is
established, autophagy acts as a pro-oncogenic factor, as it promotes tumor growth
metastasis and resistance to therapeutic drugs (revised in[47,48]). Actually, inhibition of
autophagy in HCC cells incubated with sorafenib and bevacizumab enhanced cell
lethality[49,50]. Moreover, autophagy modulation participated in oncolytic virotherapy
in a liver cancer stem cell model[51]. Thus, appropriate autophagy regulation could
effectively suppress HCC growth and metastasis.  In this section, we describe the
recent findings concerning the effect of miRNAs in autophagy and chemoresistance in
HCC.
miR26a/b
This  molecule  is  upregulated  in  some  malignant  cancers  such  as  glioma  and
glioblastoma. On the other hand, it is downregulated in some bladder tumors, breast
cancer  cell  lines  and tissues,  and anaplastic  thyroid carcinoma,  among others[52].
Particularly in HCC, miR26a/b is downregulated and its overexpression was shown
to reduce HepG2 and MHCC97-H HCC cell proliferation, migration and invasion[53].
Thus, miR26a/b might play a suppressive role in liver tumor progression.
Jin et al[54] found that DOX treatment induced autophagy and reduced miR26a/b
levels in HepG2 cells. Further, in DOX-resistant HepG2 cells this miRNA was also
downregulated. In both cell lines, incubation with autophagy inhibitors resulted in
the upregulation of miR26a/b, whereas the opposite effect was observed when an
autophagy  inducer  was  used.  This  implies  that  autophagy  can  modulate  the
expression of this miRNA[54]. Remarkably, miR26a/b overexpression in resistant cells
sensitized them to  apoptosis  induced by DOX.  Moreover,  when miR-26a/b was
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combined with DOX treatment, miR-26a/b further improved the therapeutic effect of
this drug on tumor growth in vivo. Besides, the authors performed bioinformatics
analysis and reporter gene assays and found that ULK1 (a protein that participates in
the initial stage of autophagy) is a target of miR26a/b in HCC cells (Table 2). The
overexpression of miR26a/b induced the reduction not only of ULK1, but also of
another proteins involved in autophagy (Beclin-1, ATG7 and LC3-II), on the contrary,
downregulation  of  miR26a/b induced the  increase  of  the  formers.  Thus,  miR26
modulates autophagy (suppressing ULK1 expression) in order to promote apoptosis
and sensitize HCC to chemotherapy. The authors propose that the combination of
miR26a/b with chemotherapy could introduce a new strategy to overcome cancer[54].
miR199a-5p
In triple negative breast cancer cells this miRNA is downregulated, and suppresses
cell migration and invasion[55]. On the other hand, it is upregulated in osteosarcoma
cells  and  patient  tissues  and  its  knock-down  brings  about  a  reduction  in  cell
proliferation and tumor growth[56]. In HCC cells and tissues, miR199a-5p is frequently
downregulated and its  overexpression inhibits  cell  proliferation,  migration and
invasion in vitro and in vivo[57]. Moreover, low miR199a-5p expression in HCC patients
was associated with poor prognosis.  Interestingly,  cisplatin treatment decreased
miR199a-5p levels and induced autophagy in two HCC cell lines, HuH-7 and HepG2.
However,  when  the  expression  of  miR199a-5p  was  forced,  cisplatin-induced
autophagy was inhibited and cisplatin-induced decrease of cell proliferation was
increased. Accordingly, it was found that miR199a-5p interacts with the 3’UTR region
of  ATG7  transcript  (Table  2).  Thus,  cisplatin,  via  miR199a-5p  downregulation,
increases drug resistance by inducing autophagy in HCC cells[58].
miR101
This miRNA is involved in the development and progression of oral squamous-cell
cancer. In these tissues, it is downregulated and related to patient poor prognosis[59].
In non-small cell lung cancer, it is almost undetectable and this absence is related to
lymph node metastasis and poor prognosis of patients[60].  Further, in HCC it was
observed that patients with distant metastasis had lower levels of miR101, and the
downregulation of this miRNA correlated with adverse prognosis. Besides, lentivirus-
delivered miR101 avoided tumor growth and metastasis in a HCC murine model[61].
In a study performed with HepG2 HCC cells, it was shown that miR101 induced
apoptosis upon cisplatin treatment. By using cells transfected with a sequence of RNA
that  mimics  miR101  it  was  observed  that  proteins  involved  in  the  phagosome
formation stathmin 1 (STMN1), RAS related protein (RAB5A), autophagy-related 4D
cysteine peptidase (ATG4D) and mTOR were miR101 targets (Table 2). On the other
hand,  the  use  of  a  sequence of  RNA that  specifically  binds and inhibits  miR101
increased the mRNA levels of the four genes. Moreover, miR101 inhibitor induced
much more phagosome formation than miR101 mimics, showing that the absence of
the miRNA induces autophagy. Besides, it was also demonstrated that in the presence
of cisplatin, cells with lower levels of miR101 showed less apoptosis than the ones
transfected with  miR101 mimics.  In  conclusion,  miR101 inhibits  autophagy and
increases apoptosis induced by cisplatin in HCC cells[62].
miR216b
miR216b is downregulated in colorectal cancer compared with normal tissues. High
expression of this miRNA inhibited cell proliferation, migration and invasion in this
type of  cancer  through targeting the expression of  the oncogene serine-arginine
protein  kinase  1  (SRPK1) [63].  In  cervical  cancer  tissues  and  cells  it  is  also
downregulated. Its overexpression inhibited cell proliferation in cultured HeLa cells,
suggesting a possible tumor suppressor activity in this type of cancer[64].  In HCC
patient plasma and tissues it was also found downregulated compared with healthy
volunteers and non-tumor adjacent liver tissue, respectively. Further, low expression
of miR216b correlated with patient poor prognosis[65]. In HepG2 and SMMC-7721 cells,
low levels of miR216b stimulated cell proliferation, migration and invasion, while its
overexpression produced the opposite effect[65]. Besides, miR216b levels in BEL-7402
HCC cells inversely correlated with the expression levels of metastasis associated lung
adenocarcinoma  transcript  1  (MALAT1),  an  oncogenic  long  non-coding  RNA
(LncRNA)  that  is  generally  upregulated  in  this  tumor  and  can  modulate
chemosensitivity[66]. By performing gene reporter assays, it was shown that miR216b
has  two  binding  sites  in  MALAT1.  Both  MALAT1-siRNA  and  miR216b  mimics
inhibited autophagy in BEL-7402/5-FU (BEL-7402 cells  5-FU resistant)  cells,  and
autophagy inhibition significantly increased 5-FU-induced cell apoptosis (Table 2).
Moreover, these treatments decreased the IC50 of 5-FU, DOX, and mitomycin in BEL-
7402/5-FU  cells[66].  These  results  revealed  the  relationship  between  autophagy,
WJH https://www.wjgnet.com April 27, 2019 Volume 11 Issue 4
Espelt MV et al. miRNA impact on hepatocellular carcinoma chemoresistance
351
Table 2  miRNAs and autophagy in hepatocellular carcinoma cell drug resistance
miRNA Expression Level in HCC Effect on autophagy Involvement in drugresistance Ref.
miR26a/b Downregulated in tissues and






targeting the expression of
ULK1, the key initiator of
autophagy
Sensitized HepG2 cells and
tumors to apoptosis induced
by DOX through targeting
autophagy
[53,54]
miR199a-5p Downregulated in HepG2





with the 3’UTR region of
ATG7 transcript (an
autophagy related gene)




miR101 Downregulated in cell lines
(SMMC-7721, HepG2, Bel-
4404, and 97L) and tissues,
associated with distant





expression (involved in the
phagosome formation)




miR216b Downregulated in patient
plasma and tissues, related to
poor prognosis
Inhibited autophagy, by
targeting . MALAT1 (an
oncogenic long non-coding
RNA generally upregulated
in HCC that modulates
chemosensitivity)
Sensitized BEL-7402/5-FU




miR142-3p Downregulated in tissues,
also by sorafenib treatment
Inhibited sorafenib-induced
autophagy by binding to the
3’-UTR of ATG5 and
ATG16L1
Sensitized SMCC-7721 and
HepG2 cells to sorafenib-
induced death
[69,70]
miR21 Overexpressed in patient







sorafenib resistance in Huh7
and HepG2 cells and HCC
tumors developed in mice
[72-74]
miR423-5p Overexpressed in tissues, also
elevated in serum of
sorafenib-treated patients,
and secreted in high levels
from sorafenib-treated cells
Induced autophagy Proposed as a helpful tool to
predict patient response to
sorafenib treatment
[77,78]
miRNA: MicroRNA; HCC: Hepatocellular carcinoma; ULK1: Unc-51 like autophagy activating kinase; DOX: Doxorubicin; 3’-UTR: 3’-untranslated region;
ATG: autophagy-related protein; STMN1: Stathmin 1; RAB5A: RAS related protein; ATG4D: autophagy-related 4D cysteine peptidase; mTOR: The
mammalian target of rapamycin; MALAT1: Metastasis associated lung adenocarcinoma transcript 1; 5-FU: 5-Fluoroacil; PTEN: Phosphatase and tensin
homologue.
MALAT1 and miR216b, contributing to HCC chemosensitivity.
miR142-3p
This miRNA is downregulated in non-small cell lung cancer (NSCLC) tissues and cell
lines. At high levels, it prevents tumorigenesis inhibiting the expression of one of the
high mobility group protein superfamily, HMGB1, involved in cancer cell migration
and invasion[67]. Besides, this miRNA is diminished in ovarian cancer tissues and cell
lines,  and  its  downregulation  is  related  to  poor  differentiation.  Further,  it  was
demonstrated  that  overexpression  of  miR142-3p  inhibited  proliferation  and
chemoresistance in ovarian cancer cells[68]. In HCC tissues it is also downregulated,
and  the  expression  levels  decreased  as  the  disease  progressed.  miR142-p3
overexpression inhibited BEL-7402 and SMMC-7721 HCC cell migration and invasion,
thus, it was suggested to suppress metastasis[69].
Zhang et al[70] studied the role of miR142-3p in sorafenib resistance in SMMC-7721
and HepG2 HCC cells. They showed that cells incubated with this drug presented a
higher autophagic flux than control cells in a dose- and time-dependent manner.
When autophagy was inhibited, cells become sensible to the drug. They also showed
that  miR142-3p  was  downregulated  in  HCC  cells  under  sorafenib  treatment.
Furthermore,  it  was  shown that  high levels  of  the  miRNA negatively  regulated
sorafenib-induced autophagy in HCC cells by binding to the 3’-UTR of ATG5 and
ATG16L1 mRNAs (both part of the autophagy machinery) (Table 2). Therefore, these
data indicate that miR142-3p downregulation induces autophagy by increasing the
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level of ATG5 and ATG16L1, and thus promoting sorafenib resistance in HCC[70].
miR21
This miRNA is frequently upregulated in cancer cell lines and human tumors. It is
very important in oncogenic processes as it  is  associated with high proliferation,
reduced  apoptosis,  metastasis  potential  and  invasion [71].  In  HCC  it  is  also
overexpressed and it was suggested to be related to tumor progression in patients[72].
Treatment with an oligonucleotide anti-miR21 led to the loss of viability, induction of
apoptosis  and  necrosis  in  different  HCC  cell  lines.  Further,  anti-miR21  also
diminished cell migration and suppressed clonogenic growth[73].
He et al[74] developed sorafenib-resistant HuH-7 and HepG2 HCC cells and found
that miR21 was upregulated. Interestingly, drug-sensitive parental cells transfected
with miRNA21 mimics also became resistant. It was also demonstrated that sorafenib
upregulated the expression of two key autophagic proteins (LC3-II and Beclin-1), but
the  expression  level  of  both  proteins  in  parental  cells  was  higher  than in  drug-
resistant ones. Besides, parental cells showed more acidic vesicular organelles than
resistant cells. These results indicated that autophagy is more activated in parental
cells than in the resistant ones. Interestingly, autophagy induction with rapamycin
inhibited  sorafenib-resistant  cell  growth,  indicating  that  this  process  increases
sensitivity to sorafenib in resistant cells[74]. Further, inhibition of miR21 by using an
antisense  miRNA  oligonucleotide,  re-sensitized  resistant  cells  to  sorafenib  by
promoting autophagy and stimulating apoptosis. On the other hand, miR21 mimics
reduced  autophagy,  apoptosis,  and  the  expression  of  phosphatase  and  tensin
homologue (PTEN) protein (a known target of miR21) in parental cell lines (Table 2).
Finally experiments performed with resistant cell-derived tumors established in mice
showed that  sorafenib  administration  plus  intratumoral  injection  of  anti-miR21
oligonucleotides  induced  a  reduction  in  tumor  size.  Moreover,  sorafenib
administration downregulated PTEN, upregulated LC3-II and Beclin-1 expression in
tumor lysates, and increased the activation of p-AKT. While anti-miR21 induced the
upregulation of  PTEN,  LC-II  and Beclin-1,  and reduced expression of  p-AKT[74].
Therefore, acquired sorafenib resistance might be mediated by the overexpression of
miR21 and the  inhibition of  autophagy,  probably by regulating the  PTEN/AKT
pathway.
miR423-5p
This miRNA, overexpressed in glioblastoma, was shown to enhance angiogenesis,
tumor cell growth and invasion[75]. In gastric cancer, miR423-5p was also upregulated,
and this overexpression favored cell cycle progression and decreased cell migration
and invasion[76]. Particularly in HCC tissues it is upregulated, and high levels of this
miRNA constitute a factor that increases cell invasiveness in HCC cells[77].
Interestingly, sorafenib treatment increased miR423-5p levels in conditioned media
of HepG2 and HuH-7 HCC cells and in serum of patients, suggesting a potential role
of miR423-5p as a marker of sorafenib response in HCC patients. Transfection of HCC
cells with an anti-miRNA diminished LC-II and ATG7 protein levels (an autophagic
vacuole formation protein). Accordingly, transfection with miR423-5p mimic induced
vacuole and autophagosome formation (Table 2), and the opposite was observed with
the miRNA inhibitor. In conclusion, it was suggested that this miRNA has a biological
role in autophagy in HCC and it was proposed as a helpful tool to predict patient
response to sorafenib treatment[78].
Thus, most miRNAs described here target the expression of autophagy-related
genes,  inhibiting autophagy and acting as tumor suppressors.  However,  in HCC
tissues  and  cells  many of  these  miRNAs are  downregulated,  or  their  levels  are
reduced after therapeutic drug treatment. As a consequence of this downregulation,
miRNAs do not inhibit autophagy and tumor growth and resistance is favored (Table
2).
CONCLUSION
miRNAs are deregulated in HCC cells and tissues, and they play crucial roles in the
development of chemoresistance. Emerging studies point that the modulation of ABC
transporter and/or autophagy-related gene expression could be determinant for HCC
cell  survival  under chemotherapeutic  drug treatment.  Our knowledge about the
precise mechanisms regarding miRNA involvement in resistance will lead us to find
new ways of making HCC treatment more effective. The development of miRNAs,
miRNAs mimics or anti-miRNA with long half lives and their use in combination
with chemotherapeutic drugs could be a powerful option. Even so, there are still
difficulties to overcome prior the possibility of being able to use miRNAs in clinical
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trials,  for instance, the right delivery system. Nowadays, much research is being
conducted on the use of nanoparticles to get over this trouble. Undoubtedly, more
insights  on  the  biological  processes,  signaling  pathways  and/or  molecular
mechanisms regulated by miRNAs are  needed.  Anyway,  miRNA-based therapy
together with conventional  chemotherapeutic  drugs has a  great  future in cancer
therapy.
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